Nexalin study shows insomnia improvement with 15 mA, 77.5 Hz brain stimulation

• Nexalin reported online publication of peer-reviewed results in Psychotherapy and Psychosomatics on April 20, 2026.
• Findings were already presented via publication, covering a randomized, double-blind, sham-controlled trial in chronic insomnia.
• Active treatment delivered clear improvement in sleep quality, while sham treatment showed no meaningful change.
• Neuroimaging results indicated measurable shifts in brain-network activity consistent with a plausible treatment mechanism.
• Data adds support for Nexalin DIFS platform as company advances HALO Clarity pivotal program toward planned De Novo FDA submission in insomnia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280915PRIMZONEFULLFEED9708477) on April 28, 2026, and is solely responsible for the information contained therein.